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Abstract
Introduction: Endovascular aneurysm repair (EVAR) was 
introduced as a less aggressive treatment of abdominal aortic 
aneurysms (AAA) for patients ineligible for open repair (OR).
Objective: To analyze EVAR’s incorporation impact in the 
treatment of infra-renal abdominal aortic aneurysms in our 
institution.
Methods: A retrospective study of the patients with 
diagnostic of infra-renal AAA treated between December 2001 
and December 2013 was performed. The choice between EVAR 
and OR was based on surgeon’s experience, considering patient 
clinical risk and aneurysm’s anatomical features. Patients treated 
by EVAR and by OR were analyzed. In each group, patient’s and 
aneurysm’s characteristics, surgical and anesthesia times, cost, 
transfusion rate, intraoperative complications, hospital stay, 
mortality and re-intervention rates and survival curves were 
evaluated.
Results: The mean age, all forms of heart disease and 
chronic renal failure were more common in EVAR group. Blood 
transfusion, surgical and anesthesia times and mean hospital stay 
were higher for OR. Intraoperative complications rate was higher 
for endovascular aneurysm repair, overall during hospitalization 
complication rate was higher for open repair. The average 
cost in endovascular aneurysm repair was 1448.3€ higher. Re-
interventions rates within 30 days and late re-intervention were 
4.1% and 11.7% for endovascular aneurysm repair versus 13.7% 
and 10.6% for open repair.
Conclusions: Two different groups were treated by two 
different techniques. The individualized treatment choice allows 
to achieve a mortality of 2.7%. Age ≥80 years influences survival 
curve in OR group and ASA ≥IV in EVAR group. We believe EVAR’s 
incorporation improved the results of OR itself. Patients with 
more comorbidities were treated by endovascular aneurysm 
repair, decreasing those excluded from treatment. Late re-
interventions were similar for both techniques.
Keywords: Aortic Aneurysm, Abdominal. Endovascular 
Procedures. Vascular Surgical Procedures. Health Risk.
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INTRODUCTION 
Abdominal aortic aneurysms (AAA) is a relatively common 
disease. Its prevalence increases with age. The main risk factors 
are age older than 65 years, male gender and smoking history[1]. 
As the aneurysm size increases, there is the risk of rupture[2]. 
Although some patients may present vague symptoms such 
as abdominal or back pain, the majority of aneurysms remain 
asymptomatic until rupture[3], which has a mortality rate about 
85%[4]. The goal of treatment is to exclude the aneurysm before 
rupture occurs[5].
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Treatment by open repair (OR) is practiced since 1951. In the 90s, 
endovascular aneurysm repair (EVAR) was introduced as a less invasive 
method[6], originally developed for patients considered ineligible for 
OR[7]. Its introduction aimed to improve the care provided to the 
patient offering a therapeutic possibility with less surgical aggression 
initially without thinking that could compete with OR. Older patients 
with major comorbidities previously excluded from treatment have 
become candidates for EVAR allowing a reduction in the number 
of patients without conditions for treatment over the years. But the 
selection of the treatment method to each patient is not always 
clear and is based on the results of randomized studies, national/
international series and individual choice based on surgeon’s 
opinion, considering patient clinical risk and aneurysm features.
There is strong evidence of OR’s durability, but there are 
few long-term results for EVAR. So, there is still an uncertainty 
concerning EVAR’s durability and its overall long-term efficacy 
when compared to OR[8]. This lack of knowledge about the 
future behavior implies a greater need for clinical and imaging 
surveillance which could represent higher costs.
Several studies compared EVAR to OR particularly regarding 
the perioperative and long-term mortality, re-intervention rates 
and cost-effectiveness, sometimes with diverging results.
The Clinical Practice Guidelines of the European Society of 
Vascular Surgery suggest that vascular surgical referral centers 
must have an operative mortality for elective OR less than 5% 
and for EVAR less than 2%[9].
Having regard to selection of the best treatment to be used 
for each patient and knowing that these treatment methods are 
complementary and not competitive, the purpose of this study 
is to analyze the impact of EVAR’s incorporation in the treatment 
of infra-renal AAA in our institution.
METHODS
A retrospective study of the patients with the diagnostic of 
infra-renal AAA treated in our institution between December 
2001 and December 2013 was performed. Patients with the 
diagnosis of infra-renal AAA with diameter equal or superior to 
5cm and patients with infra-renal AAA with diameter inferior to 
5cm but with iliac aneurysms with diameter equal or superior to 
3cm were included in our study.
The choice between EVAR and OR was individualized for 
each patient, based on surgeons’ opinion, considering patient 
clinical risk and aneurysm’s anatomical features.
During this period, a total of 292 patients were treated in our 
institution with the diagnostic of infra-renal AAA, 171 (58.6%) by 
EVAR and 121 (41.4%) by OR.
We analyzed the group of patients treated by EVAR and by 
OR and, for each group, we studied patient’s and aneurysm’s 
characteristics, surgical and anesthesia average times, need for 
blood transfusion, intraoperative complications, mean hospital 
stay, re-intervention rates (within 30 days and after), mortality 
rate (during hospitalization and within 30 days) and survival 
curves. We studied costs associated to EVAR and to OR and the 
relation between costs and age and costs and American Society 
of Anesthesiologists (ASA) classification.
The mean follow-up time was 32.4 months. The follow-up 
was performed with computerized tomography (CT) in the 3rd 
and 9th month after treatment and then yearly or every time it 
seems clinically relevant.
The statistical method used evaluates the normal distribution 
of the continuous variables using the Kolmogorov-Smirnov test. 
The comparison between two groups of patients was based on 
Student’s t test for variables that approximately followed a normal 
distribution and the Mann-Whitney-Wilcoxon test in the event that 
the assumptions of normality or equality of variances were not 
observed. Comparison of more than two groups was based on 
analysis of variance and the Kruskal-Wallis test, when the assumptions 
of normality and homogeneity of variances were absent.
RESULTS
The mean age was 74.1±8.9 years in the EVAR group and 
69.6±8.7 years in the OR group, this variable proved to have 
statistical relevance (P<0.001). The treatment performed 
according to the age group was also studied (Figure 1). In this 
sense, the patients were divided into three groups: with age 
up to 70 years, between 70 and 80 years and above 80 years. 
For each group, respectively, the treatment was EVAR in 31.6%, 
38.6%, 29.8% and OR in 47.1%, 43%, 9.9%. A statistically significant 
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Fig.1 – Distribution of the type of treatment according to age group.
relationship was observed (P<0.001) with the younger group 
most often treated by OR and the older one most often by EVAR.
In relation to gender, 94.2% of patients in the EVAR group 
were male and 5.8% were female. In OR group, 95% were male 
and 5% were female. There was no relationship with statistical 
significance among variables (P=0.478).
Regarding the presence of aortic atherosclerotic disease risk 
factors we studied hypertension, diabetes mellitus, dyslipidemia, 
cerebrovascular disease, peripheral arterial disease and active/
non-active smoking. No statistically significant relationship was 
observed for high blood pressure (84.2% in the EVAR group vs. 
87% in the OR group, P=0.610), non-active smoking (58.8% in 
EVAR vs. 57% in OR; P=0.807), dyslipidemia (67.6% in EVAR vs. 
61.4% in OR, P=0.134), diabetes mellitus (18.2% in EVAR vs. 11.4% 
in OR, P=0.134) and peripheral arterial disease (18.2% in EVAR 
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vs. 19.3% in OR, P=0.877). A statistically significant relationship 
was observed for active smoking (16.5% in EVAR vs. 31.5% in 
OR, P=0.004) and for cerebrovascular disease (19.4% in EVAR vs. 
10.5% in OR, P=0.048).
Associated diseases (heart, lung or kidney diseases) were 
studied for each group. Regarding the presence of cardiac 
disease studied were higher in the EVAR group with a statistically 
significant relationship with ischemic cardiac disease present 
in 53% of the patients in the EVAR group vs. 40.4% of those in 
OR group (P=0.039), valvular disease present in 27% of those 
submitted to EVAR vs. 4.4% of those in the OR group (P<0.001), 
dysrhythmia present in 37.2% in the EVAR vs. 12.4% in the OR 
group (P<0.001) and cardiac insufficiency present in 45.1% of the 
patients in the EVAR group vs. 20.2% in the OR group (P<0.001). 
Regarding pulmonary disease, chronic obstructive pulmonary 
disease (COPD) was present in 24.1% of patients in the EVAR 
group and in 26.8% in the OR group, no statistically significant 
relationship was observed (P=0.672) and respiratory failure 
was present in 5.6% of the patients in the EVAR group vs. 0.9% 
in the OR group, an almost statistically significant relationship 
was observed (P=0.051). Regarding renal disease, a statistically 
significant relationship was observed for the presence of chronic 
renal insufficiency (21.3% of patients treated by EVAR vs. 8.8% in 
OR, P=0.007) but wasn’t observed for chronic renal insufficiency 
in hemodialysis replacement therapy (1.8% of the patients in the 
EVAR vs. 0 in the OR group, P=0.274) or chronic renal insufficiency 
in kidney transplantation replacement therapy (2.5% of those in 
the EVAR vs. 0.9% in the OR group, P=0.651).
As regards the ASA physical status classification our patients 
were in one of three categories: ASA II (mild systemic disease), 
ASA III (severe systemic disease) or ASA IV (systemic disease 
threatening life). The frequency was, respectively, 15.6%, 71.3% 
and 13.1% in the EVAR group and 30.3%, 62.4% and 7.3% in the 
OR group. A statistically significant relationship was observed 
(P=0.001) with patients classified as class II more commonly 
treated by OR and class IV by EVAR.
Aneurysm characteristics were also studied. Regarding the 
anatomical type divided into aortic, bilateral aorto-iliac, right 
aorto-iliac and left aorto-iliac this was respectively 65.5%, 11.7%, 
15.2% e 7.6% in the EVAR group and 80.2%, 9.0%, 8.1% e 2.7% in 
the OR group. A statistically significant relationship was observed 
(P=0.045) with aortic aneurysms treated most commonly by OR 
and aorto-iliac aneurysms (right and left) by EVAR.
Regarding the aneurysm etiology, divided into degenerative, 
inflammatory and other etiology, was respectively 93.5%, 5.3% 
and 4.1% in the EVAR group and 97.3%, 2.7% and 0 in the OR 
group, no statistically significant relationship was observed 
(P=0.092). The aneurysm etiology was also studied dividing 
into only two etiologies degenerative and inflammatory, which 
represent respectively 97.5% and 2.5% in the EVAR group vs. 
97.3% and 2.7% in the OR group, no statistically significant 
relationship was observed (P=0.001).
Aneurysm morphology, divided into fusiform and saccular 
was respectively 94.7% and 5.3% in the EVAR group vs. 72.3% and 
27.7% in the OR group, a statistically significant relationship was 
observed (P<0.001) with saccular aneurysms most commonly 
treated by OR.
As regards the aneurysm diameter, it was 62.4±14.8 mm in 
the group treated by EVAR and 64.8±15.7 mm in the OR group. 
No statistically significant relationship (P=0.201) was observe.
Blood transfusion was needed in 23.1% in the EVAR group vs. 
77.6% in the OR group, a statistically significant relationship was 
observed between these variables (P<0.001).
The mean anesthesia time was 174.4±63.2 minutes in 
the EVAR group and 292.6±79.5 minutes in the OR group, a 
statistically significant relationship was observed between these 
variables (P<0.001). The mean surgical time was 102.7±48.4 
minutes in the EVAR group and 190.1±61.5 minutes in the 
OR group, a statistically significant relationship was observed 
between these variables (P<0.001).
Regarding EVAR’s intraoperatory complications, we 
considered endoleaks requiring additional treatment, arterial 
dissection/thromboses or other situations that require some 
additional intervention. In OR group, we considered vascular or 
visceral damage. Intraoperative complications rate was 23.4% 
in the EVAR group and 14.4% in the OR group, a statistically 
significant relationship was observed (P<0.001). The overall rate 
of complications during hospitalization was higher in the OR 
group (38% in the OR group vs. 10.8% for EVAR), with a statistically 
significant relationship (P<0.001).
We analyzed the costs associated with an EVAR and OR 
procedures (Table 1). The average cost in EVAR was 1.448,3€ 
higher in comparison to OR. When we studied the relation 
between costs and age (Table 2) and costs and ASA classification 
(Table 3), no statistically significant relation was observed 
regarding age, but for both groups a statistically significant 
relation was observed between costs and ASA classification with 
patients classified ASA IV or above implying a significant higher 
cost in EVAR and in OR.
The mean duration of hospitalization was 6.3±7.1 days for the 
EVAR group and 12.9±16.6 days for the OR group, a statistically 
significant relationship was observed between these variables 
(P<0.001).
The overall mortality during hospitalization with the use of 
both techniques was 2.7% (1.2% in the EVAR group and 5% in the 
OR group), no statistically significant relationship was observed 
(P=0.07). Mortality within 30 days was 1.2% in the EVAR group 
and 5% in the OR group. We also studied the survival curves for 
EVAR and for OR (Figure 2). The median survival was 8.5 years 
with a standard deviation of 0.5 (95% CI - 7.6 to 9.5) in the EVAR 
Table 1. Global costs. 
Mean Median Std. Deviation Minimum Maximum Percentil 25 Percentil 75
EVAR 11,404.00 € 10,387.70 € 4,489.40 € 9,081.50 € 50,779.70 € 9,979.30 € 11,141.70 €
Open repair 9,955.70 € 7,189.00 € 10,062.90 € 3,819.00 € 95,144.00 € 5,635.00 € 10,561.70 €
Machado R, et al. - EVAR’s Incorporation in a Vascular Surgery Unit
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group and 8.2 years with a standard deviation of 0.4 (95% CI- 7.3 
to 9.0) in the OR group. We analyzed relation between survival 
curves and ASA classification and age. We found that in EVAR 
group the median survival in the group classified as ASA II was 
5.2 years with a standard deviation of 0.4 (95% CI – 4.4 to 6), in the 
group classified as ASA III was 9.4 years with 0.5 standard deviation 
(95% CI - 8.4 to 10.5) and in the group classified as ASA IV or higher 
was 4.6 years with a standard deviation of 0.8 (95% CI – 3.2 to 
6.1), a statistically significant relation was observed with patients 
classified as ASA IV or more having a lower mean survival (Figure 3), 
no statistically significant relation was observed in the OR group. 
When we analyzed the relation between age and survival curves 
we realized that, in the OR group (Figure 4) the median survival for 
patients under 70 years was 8.7 years with a standard deviation 
of 0.6 (95% CI - 7.6 to 8.9), in the group between 70 and 80 years 
was 7.5 years with a standard deviation of 0.6 (95% CI - 6.3 to 8.7) 
and in the group of patients older than 80 years was 4 years with a 
standard deviation of 0.9 (95% CI - 2.2 to 5.8), statistically significant 
relationship was observed patients older than 80 years has a lower 
mean survival in comparison to younger groups, in EVAR group no 
statistically significant relationship was observed.
Regarding re-intervention rate within 30 days was 4.1% 
for EVAR and 13.7% for patients treated by OR. Concerning 
EVAR, 28.6% of complications were related to type 1 endoleak, 
14.3% thrombosis with need for an axillary-femoral bypass 
and 57.1% wound complications. With regard to the OR, of all 
the re-interventions within 30 days, 24.7% represented drain 
of retroperitoneal haematoma, 18.9% exploratory laparotomy, 
18.9% revascularization surgery, 6.6% colectomy, 13% wound 
Table 2. Costs and age.
Mean Median
Std. 
Deviation
Minimum Maximum Percentil 25 Percentil 75 ES
EVAR <70 years 11,658 € 10,226.80 € 6,157.80 € 9,270 € 50,779.70 € 9,867.50 € 10,996.70 € N
70-80 years 11,110.30 € 10,484.70 € 2,163 € 9,433 € 20,979 € 10,017.80 € 11,317 €
>80 years 11,521.80 € 10,371.30 € 4,752.80 € 9,081.50 € 40,240.70 € 10,007.80 € 11,068.40 €
Open repair <70 years 9,478.80 € 6,218.90 € 12,925.10 € 3,839.90 € 95,144 € 5,189.50 € 8,217.30 € N
70-80 years 10,836.60 € 9,370.80 € 6,549.80 € 3,819 € 36,003 € 6,180.40 € 13,155.80 €
>80 years 8,607.60 € 6,534.80 € 3,911.50 € 4,592 € 14,340 € 5,476.60 € 12,424.40 €
Table 3. Costs and ASA classification.
Mean Median
Std. 
Deviation
Minimum Maximum Percentil 25 Percentil 75 ES
EVAR ASA II 11,356.50 € 9,990 € 6,185.30 € 9,270 € 40,240.70 € 9,694.20 € 10,431.80 € Y
ASA III 10,776.70 € 10,371.30 € 1,849 € 9,081.50 € 22,643.20 € 10,012 € 10,870.80 €
ASA IV 14,725.20 € 11,926.20 € 8,858.40 € 9,644.30 € 50,779.30 € 10,631 € 15,539.30 €
Open repair ASA II 9,613.50 € 6,471.10 € 7,434.20 € 4,174.20 € 36,003 € 5,707.30 € 10,367.80 € Y
ASA III 8,758 € 7,783.20 € 4,469.80 € 3,819 € 24,901.70 € 5,557.30 € 10,829.20 €
ASA IV 21,729.80 € 9,762.20 € 30,464.90 € 4,761.50 € 95,144 € 6,653.10 € 23,607.20 €
Fig. 2 – Survival curves in EVAR and OR groups.
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surgery and 18.9% incisional hernia repair. With a mean follow-
up of 32.4 months our protocol follow-up involves CT in the 3rd 
and 9th month after treatment and then yearly besides, CT was 
also performed every time it seems clinically pertinent. After 30 
days, re-intervention rate was 11.7% for EVAR and 10.6% for OR, 
no statistically significant relation was observed between these 
variables (P=0.56). Concerning EVAR, of all the re-interventions 
after 30 days, 72.6% were related to type 1 endoleak, 4.8% to type 2 
endoleak, 9.5% to type 3 endoleak and 9.5% because of endograft 
branch thrombosis. In the OR group, 90.9% were for incisional 
hernia repair and 9.1% (1 case) correction of a false aneurysm.
Fig. 4 – Survival curves in OR group according to age group.
Table 4. ASA classification of the patients treated.
ASA I – Healthy 
Patient 
(%)
ASA II – Mild 
Systemic Disease 
(%)
ASA III – Severe 
Systemic Disease 
(%)
ASA IV – Systemic 
Disease Threatening 
Life (%)
Our Institution
EVAR __ 15.6 71.3 13.1
OR __ 30.3 62.4 7.3
DREAM trial
EVAR 21.6 69.6 8.2 __
OR 25.3 60.9 13.8 __
ACE trial
EVAR 10.7 66.0 22.7 1.3
OR 8.0 59.7 32.2 __
DISCUSSION
From an overall assessment of this population, we conclude 
that the characteristics of patients treated by EVAR and by OR 
are different. Patients treated by EVAR are generally older and 
with more associated diseases. To point out that when we 
studied chronic renal insufficiency in replacement therapy we 
haven’t observed any relation probably due to the small number 
of patients treated. In fact only 3 patients on hemodialysis 
were treated and all of them were treated by EVAR. Only 5 
renal transplant patients were treated, 4 by EVAR and 1 by OR. 
These observations are in agreement with our results when we 
Fig. 3 – Survival curves in EVAR group according to ASA classification.
<= 69
70-79
>= 80
2 - censored
3 - censored
>= 4 - censored
2
3
>= 4
2 - censored
3 - censored
>= 4 - censored
AGE
ASA (cl)
103
Brazilian Journal of Cardiovascular Surgery 
Braz J Cardiovasc Surg 2016;31(2):98-105Machado R, et al. - EVAR’s Incorporation in a Vascular Surgery Unit
studied ASA classification. “The Dutch Randomised Endovascular 
Aneurysm Management Trial”, 2005, (DREAM trial) and the 
“Anevrysme de l’aorte abdominale, Chirurgie versus Endoprothese” 
(ACE trial) are two randomized studies that also studied ASA 
classification in patients included (Table 4). In these studies, the 
majority of patients selected for treatment belonged to class 
II of ASA classification (mild systemic disease). In contrast, the 
majority of patients treated in our institution belong to class 
III (severe systemic disease). Additionally, in DREAM trial there 
were no patients classified as class IV and they represent only 
1.3% of the patients treated, all of them by EVAR, in ACE trial. It 
could be explained with the fact that in DREAM trial only patients 
eligible for both treatments were included, this can eventually 
have conditioned that some patients classified as ASA IV were 
considered not eligible for OR and so not included in the trial. 
The ACE trial only included relatively good-risk patients and all 
patients classified as ASA IV were treated by EVAR. These results 
reinforce EVAR as an option for patients with ASA classification III 
or IV whom can now be treated with less risk[10].
Regarding to gender, our results demonstrate the equal offer 
of both techniques to both genders and point out the higher 
prevalence of the disease in male gender as described in the 
literature.
When we studied the aneurysm’s etiology (divided into 
degenerative, inflammatory and others) no statistically significant 
relationship was observed but it should be noted that all 
aneurysms classified as other etiologies were treated by EVAR. As 
for aneurysm size measured by its diameter no differences were 
observed in both groups proving that the therapeutic indication 
is independent of the technique used.
Regarding blood transfusion necessity we observed a 
clear advantage in the EVAR. We observed almost a reversal 
in necessities with 76.4% in the EVAR group not requiring 
transfusion vs. 77.6% in the OR group requiring blood transfusion. 
At a time when the availability of blood is scarce this is of great 
importance. It also opens a door for those who for religious 
reasons do not accept transfusion of blood products.
As regards time consumption in the operating room and 
surgeon’s time consumption measured respectively by the 
duration of anesthesia and the surgery time there was a clear 
advantage in the treatment by EVAR with reduction of both 
times. Relatively to the overall hospital stay there was also a clear 
advantage in the EVAR group (6.6 days less than for OR). At a time 
when reducing inpatient bed is expected, EVAR can be useful. 
The average cost in EVAR was 1.448,3€ higher in comparison to 
OR. ASA classification equal or higher than 4 was associated with 
higher costs in both groups.
Prospective randomized trials as “The United Kingdom 
Endovascular Aneurysm Repair Trial 1” (EVAR 1 trial), “Open versus 
Endovascular Repair Veterans Affair Cooperative Study” (OVER trial) 
and the already cited ACE and DREAM trials have also recognized 
a reduced in the need for transfusion, shorter surgical time and 
shorter duration of hospitalization among patients treated by 
EVAR when compared to those treated by open repair[11-13].
Regarding complications (intraoperative and during 
hospitalization) only the first shows a tendency to be more 
numerous in the EVAR group (Figure 5). The overall rate of 
complications during hospitalization was significantly higher in 
the OR group and we concluded that most of these complications 
were medical and whose treatment was also medical. Actually 
OR showed a rate of complications during hospitalization of 
38%, but the rate of re-interventions within 30 days was only 
13.7% which points out that most of the complications did not 
require re-intervention. In comparison, the EVAR had a lower rate 
of complications during hospitalization (10.8%) and a lower rate 
of re-interventions within 30 days (4.1%).
Regarding mortality, the use of both techniques allowed to 
reach a global mortality during hospitalization of 2.7% (1.2% in the 
EVAR group and 5% in the OR group). Although not statistically 
significant, the mortality difference of the two groups tends to 
be significant (P=0.07). Considering that the EVAR group has a 
greater clinical risk as we have already concluded, we can infer 
benefit in terms of early mortality that this technique arrived. The 
Table 5 shows the mortality rates obtained in our institution and 
those published in some prospective randomized studies (EVAR 
1, DREAM, OVER and ACE trials). Our mortality rates are similar of 
those obtained in those prospective randomized trials. In 2011, 
Mani et al.[14] have published “Treatment of Abdominal Aortic 
Aneurysm in Nine Countries 2005-2009: A Vascunet Report”, 
where the biggest international registration of patients with the 
diagnosis of AAA treated was analyzed. This registration involves 
nine countries record (seven nationally - Denmark, Hungary, Italy, 
Norway, Sweden, Switzerland and the United Kingdom and two 
regional - Australia and Finland). Part of the results is shown in 
Table 6 where we made a comparison with the results obtained 
in our institution. We can conclude that our findings are similar 
to those published in this international series. 
Long-term mortality rate associated with the two techniques 
has been widely studied. The EVAR 1, DREAM and OVER trials 
were in agreement in getting an early benefit in the perioperative 
mortality with EVAR but this benefit is lost during follow-up and 
no differences exist between the two groups in the long-term 
treatment. In the EVAR 1 trial the authors consider that the loss 
of this initial benefit throughout the study is at least in part, 
Fig. 5 – Complications and re-interventions according to the type 
of treatment.
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Table 5. Intraoperative/during hospitalization mortality rate.
Patients treated by EVAR (%) Patients treated by Open Repair (%)
Our Institution 1.2 5
EVAR 1 1.7 4.7
DREAM 1.2 4.6
OVER 0.5 3.0
ACE 1.3 0.6
Table 6. Results obtained from Mani et al.[14] regarding treatment of abdominal aortic aneurysm in nine countries 2005 e 2009: A 
Vascunet Report 2011 and in our institution.
National Regional
Denmark Hungary Italy Norway Sweden Switzerland
United 
Kingdom
Australia Finland
Our 
Institution
A 2500 269 9107 2707 4134 1814 8789 1814 293 292
B 2005-2009 2008-2009 2007-2009 2005-2008 2005-2009 2005-2008 2005-2009 2005-2009 2007-2009 2001-2013
C 71.1 68.3 72.6 72.2 72.1 70.8 73.6 74.65 71.1 74.11
D 23.8 17.5 49 29 43.9 37.4 49.4 56 14.7 58.6
E NR 6.2 NR 6.5 6.4 NR 7.1 6.5 6.4 6.241
F 1.2 4.3 0.9 0.3 1.9 2.6 1.8 1.3 2.3 1.2
G 4 2.3 2.2 2.7 3.2 3.6 5.3 3.8 4.4 5
A=number of cases; B=years of study; C=mean age (years); D=EVAR rate (%); E=mean aneurysm diameter (cm), F=operatory 
mortality rate for EVAR (%); G=operatory mortality rate for open repair (%); (1)=for the group of patients treated by EVAR; NR=not 
reported
due to late endograft ruptures. The authors also believe that 
EVAR is associated with a higher rate of graft complications, 
more re-interventions and higher cost. A similar conclusion was 
presented in the DREAM and ACE trials. In contrast, the OVER 
trial revealed no significant difference in re-intervention rates in 
the both groups. In our institution the re-intervention rate after 
30 days was not significantly different between the two groups 
corroborating the OVER trial and going against EVAR 1, DREAM 
and ACE trials.
CONCLUSION
The selection of the treatment method to be used is not clear. 
At one extreme, we have a young patient with low clinical and 
anatomic risk and a complex aneurysm anatomy for which OR 
is the election. At the other extreme, we have an elderly patient 
with high clinical/anatomical risk with good aneurysm anatomy 
and EVAR is the election. But in most situations in clinical practice 
these characteristics are mixed and hinder the decision.
Our study showed that the two groups have different clinical 
conditions that make a comparison difficult. The EVAR group is 
a presents major clinical risk as demonstrated and it can lead 
to increased mortality during follow-up of these patients not 
necessarily related to its AAA.
Assessing the institutional impact of the EVAR’s introduction 
in the treatment of patients with infra-renal AAA, we conclude 
that this method allowed the achievement of an overall during 
hospitalization mortality of 2.7% (1.2% for EVAR and 5% for OR), 
allowing us to achieve the objectives set by the European Society 
of Vascular Surgery which states that reference centers must 
have, for elective procedures, a mortality rate lower than 2% for 
EVAR and less than 5% for OR. We also believe that by offering 
EVAR for these patients with more comorbidities (that would 
eventually be treated by OR if EVAR had not been introduced), 
we improved the results of OR itself. We also concluded that age 
older than 80 years influences the survival curve in the OR group 
and ASA classification equal or above 4 influences the survival 
curve in the EVAR group.
Treatment by EVAR has been pointed out as having higher 
costs in part by the higher rate of re-interventions and our study 
contradicted this aspect and reinforced the confidence in a cost-
containment strategy.
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